Vedolizumab Therapy With or Without an Immunosuppressant for the Therapy of Inflammatory Bowel Disease: A Single Center Experience

被引：0
|
作者：
Chilukuri, Prianka
Xu, Huiping
Bohm, Matthew
Sagi, Sashivar
Fischer, Monika
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)32748-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1906
引用
收藏
页码：S812 / S813
页数：2
相关论文
共 50 条
  • [31] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [32] Treatment Algorithm for Inflammatory Bowel Disease Patients Who Fail Vedolizumab as Salvage Therapy
    Cohen-Mekelburg, Shirley
    Ghosh, Gaurav
    Gold, Stephanie
    Schneider, Yecheskel
    Scherl, Ellen J.
    Steinlauf, Adam
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1479 - S1480
  • [33] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [34] Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease
    Pugliese, Daniela
    Privitera, Giuseppe
    Schepis, Tommaso
    Larosa, Luigi
    Onali, Sara
    Scaldaferri, Franco
    Gasbarrini, Antonio
    Caprioli, Flavio
    Armuzzi, Alessandro
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (06) : E1483 - E1487
  • [35] Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
    O'Connell, J.
    Ismail, M. S.
    McCormack, M.
    McDonagh, P.
    Argue, R.
    Breslin, N.
    Crowley, V.
    Cullen, G.
    Doherty, G. A.
    Dunne, C.
    Hartery, K.
    MacCarthy, F.
    McKiernan, S.
    Mulcahy, H.
    O'Connor, A.
    O'Morain, C.
    Ryan, B.
    Sheridan, J.
    Healy, M.
    McNamara, D.
    Kevans, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S308 - S309
  • [36] Real World Experience of Ustekinumab Therapy in Patients at a US Tertiary Inflammatory Bowel Disease Center
    Cleveland, Noa Krugliak
    Normatov, Inessa
    Buisson, Anthony
    Glick, Laura R.
    Zmeter, Nada
    Pekow, Joel
    Cohen, Russell
    Rubin, David T.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S376 - S376
  • [37] Assessment of Serum Biomarkers associated with Vedolizumab Therapy Response in Inflammatory Bowel Disease.
    O'Connell, J.
    Argue, R.
    Dunne, M.
    O'Connell, F.
    Breslin, N.
    Cullen, G.
    Doherty, G.
    Dunne, C.
    Hartery, K.
    Ismail, M. S.
    MacCarthy, F.
    McDonagh, P.
    McKiernan, S.
    McNamara, D.
    Mulcahy, H.
    O'Connor, A.
    Ryan, B.
    Sheridan, J.
    O'Sullivan, J.
    Kevans, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I299 - I299
  • [38] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [39] Effect of vedolizumab therapy on whole blood transcriptional profiles in patients with Inflammatory Bowel Disease
    Haglund, S.
    Soderman, J.
    Almer, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S592 - S592
  • [40] Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A single-center experience
    Sina, M.
    Pemaj, X.
    Djegsi, A.
    Telaku, S.
    Prifti, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1361 - I1361
12345